A study of long-term efficacy and safety of calcipqotriol hydrate/betamethasone dipropionate ester fixed dose combination product in patients with psoriasis vulgaris

A study of long-term efficacy and safety of calcipqotriol hydrate/betamethasone dipropionate ester fixed dose combination product in patients with psoriasis vulgaris - A study of long-term efficacy and safety of calcipqotriol hydrate/betamethasone dipropionate ester fixed dose combination product in patients with psoriasis vulgaris

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025083

Enrollment

100

Registered

2017-05-15

Start date

2015-06-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis vulgaris

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age: 20 years old or over 2) Symptom: Manageable within 10g/day of Dovobet 3) Sex, inpatient/outpatient, does not matter

Exclusion criteria

Exclusion criteria: 1) pregnant, or possibly pregnant women 2) subjects contraindicated by package insert 3) subjects judged unsuitable by physicians 4) subjects who are going to receive oral or injective steroid, cyclosporine, methotrexate, biologics, ultraviolet therapy, herbal medication against psoriasis within the trial period., 5) subjects who used Dovobet within 4 weeks before starting the trial.

Design outcomes

Primary

Measure	Time frame
comparison of m-PASI score at week 0, week 4, week24, and week52.	—

Secondary

Measure	Time frame
PGA and safety	—

Countries

Japan

Contacts

Public ContactShinichi Imafuku

Fukuoka University Department of dermatology

dermatologist@mac.com092-801-1011

Outcome results